{"schema_version":"secwatch.filing_event.v1","accession":"0001021771-24-000027","form_type":"8-K","ticker":"BRTX","cik":"0001505497","company_name":"BioRestorative Therapies, Inc.","filed_at":"2024-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.373061+00:00","generated_at":"2026-06-06T09:06:22.016922+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioRestorative reports positive preliminary Phase 2 data for BRTX-100 in chronic lumbar disc disease","bullets":["Preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 presented at ORS 2024 Annual Meeting.","Pain and function scales (VAS, ODI, RMDQ, FRI) show positive trend vs baseline at both follow-up points.","No notable safety signals observed in the ongoing study for chronic lumbar disc disease.","Company will host webcasted conference call today Feb 5 at 8:30am ET to discuss data and clinical update."],"urls":{"canonical":"https://secwatch.observer/filing/0001021771-24-000027","json":"https://secwatch.observer/filing/0001021771-24-000027.json","markdown":"https://secwatch.observer/filing/0001021771-24-000027.md","text":"https://secwatch.observer/filing/0001021771-24-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1505497/000102177124000027/0001021771-24-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1505497/000102177124000027/brt8k2524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:06:22.016922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}